Fibrosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Fibrosis. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Fibrosis receives a directional strategic score of 59/100, combining unmet need (61/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (95/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.

The reproducible entity is Patsnap disease ID a129f757d3124c448c547ab7ad5d2882 with MeSH identifier D005355. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta‐Analysis The Epidemiology of Primary Biliary Cholangitis in EuropeanCountries: A Systematic Review and Meta-Analysis

2.1.SearchStrategy. ,e Medline and Scopus databases were searched for studies with information on either the inci- dence or prevalence of PBC. ,e last search was run on 7 July 2020. A literature review was created using the following search terms: (“epidemiology” or “prevalence” or “inci- dence”) AND (“primary biliary cirrhosis” or “primary biliary cholangitis” or “autoimmune liver disease” or “sclerosing cholangitis” or “biliary liver cirrhosis”). Medical Subject Headings (MESH) were used to increase the precision and efficiency of the search. No language, publication date, or publication status restrictions were imposed. In addition, we expanded the search using the reference lists of relevant review articles identified during the search. Two authors independently screened the literature review using titles and abstracts and assessed full texts where eligible. Disagree- ments over the inclusion of articles were resolved by dis- cussion with a senior hepatologist. 2.2. Inclusion and Exclusion Criteria. Studies were included if they met the following criteria: (1) the study was original research; (2) the study reported a prevalence or incidence (or it reported raw data that allowed the calculation of esti- mates); (3) the study was conducted in Europe; and (4) the study was published in 2000 or later. Exclusion criteria for the meta-analysis were as follows: (1) the study was a review article; (2) the study was a genome study or an animal study; (3) the study described the epi- demiology of PBC among hospitalized patients; and (4) the study did not specifically describe patient

Review the epidemiology source

Epidemiology evidence 2: Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database

18. Gazda J, Drazilova S, Janicko M, Jarcuska P. The epidemiology of primary bili­ ary cholangitis in European countries: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2021;2021:9151525. 19. Heetun Z, Maher N, Buggy A, Carroll P, Aftab A, Courtney G. Prevalence and epidemiology of autoimmune hepatitis and primary biliary cirrhosis across the South-Eastern regional health board [Abstract 50]. Ir J Med Sci. 2015;184(Suppl 3):94. 20. Gatselis NK, Zachou K, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, et al. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. Eur J Intern Med. 2017;42:81–8. 21. Marzioni M, Bassanelli C, Ripellino C, Urbinati D, Alvaro D. Epidemiology of primary biliary cholangitis in Italy: evidence from a real-world database. Dig Liver Dis. 2019;51(5):724–9. 22. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33(1):99–103. 23. Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52(2):571–7. 24. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–9. 25. Escorsell A, Parés A, Rodés J, Solís-Herruzo JA, Miras M, de la Morena E. Epide­ miology of primary sclerosing cho

Review the epidemiology source

Epidemiology evidence 3: Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review Epidemiology of pulmonary arterial hypertension and chronicthromboembolic pulmonary hypertension: identification of themost accurate estimates from a systematic literature review

All but one18 incidence estimates were incidence propor- tions (incidence based on person at risk) rather than inci- dence rate (incidence based on person-time at risk). Studies calculated incidence using the last year of observation (n ¼ 19), an average of each annual incidence of the period (n ¼ 4) and an average over the whole observation period (n ¼ 4). Point prevalence using the last year of observation was reported in 12 studies. Period prevalence using the last year of observation was reported in 11 studies, and two used the whole observation period. For simplicity, the terminol- ogy ‘incidence’ and ‘prevalence’ are used consistently in this review. Supplementary Table 3 contains full details on how incidence and prevalence were calculated and reported. Estimates for incidence are presented in patient per million (ppm) per year and estimates for prevalence are presented in ppm at a given time. Incidence and prevalence of PAH in adults The published estimates of PAH epidemiology in adults are summarised in Table 1. The publications include five national systematic registries, eight non-systematic regis- tries, five claims/administrative databases and three clinical Fig. 1. PRISMA flow diagram. PH: pulmonary hypertension. 4 | Epidemiology of PAH and CTEPH Leber et al. Table 1. Study details and epidemiology estimates from identified studies investigating PAH epidemiology in adults. Notes: Studies are ordered by study design and then in ascending order of incidence estimate. Estimates are rounded to one decimal place, except where only integers were published. aPAH defi

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Fibrosis, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Fibrosis thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: ALK5

Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis (PubMed:33914044). The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.

The mechanism anchor is TGFBR1. It is a pathway hypothesis, not a claim that every Fibrosis patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 3232 registered studies. Recent sampled records include:

• ChiCTR2600130558 — The impact of remote exercise-based cardiac rehabilitation on the pulmonary and cardiac functions as well as myocardial fibrosis in patients after PCI for coronary heart disease; Not yet recruiting; Early Phase 1; sponsor Affiliated Hospital of Jiangsu University; enrollment 40.
• NCT07775638 — Detecting Liver Fibrosis in Patients At-risk (STELIR); Not yet recruiting; Not Applicable; sponsor Helse Stavanger HF; enrollment 1200.
• NCT07774455 — Pacritinib Effectiveness in Real-world Settings (PACER); Not yet recruiting; Not Applicable; sponsor Swedish Orphan Biovitrum AB, IQVIA RDS, Inc.; enrollment 60.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

The search returned 10 recent directly matched transaction records:

• Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression (2026-06-08). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• United Immunity Acquires Macrophage Assets from Carisma Therapeutics (2026-05-21). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis (2024-12-10). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate TGFBR1 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Fibrosis merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if TGFBR1 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Fibrosis is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.